enVVeno Medical Corporation (NASDAQ:NVNO) Short Interest Up 24.7% in February

enVVeno Medical Corporation (NASDAQ:NVNO - Get Free Report) saw a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 532,700 shares, a growth of 24.7% from the February 13th total of 427,100 shares. Approximately 3.1% of the company's stock are short sold. Based on an average daily trading volume, of 135,100 shares, the short-interest ratio is currently 3.9 days.

Institutional Investors Weigh In On enVVeno Medical

Several institutional investors and hedge funds have recently modified their holdings of NVNO. JPMorgan Chase & Co. acquired a new stake in shares of enVVeno Medical in the 4th quarter valued at $816,000. Westside Investment Management Inc. lifted its position in enVVeno Medical by 132.0% during the 4th quarter. Westside Investment Management Inc. now owns 205,025 shares of the company's stock worth $619,000 after acquiring an additional 116,650 shares during the last quarter. Corsair Capital Management L.P. acquired a new position in enVVeno Medical during the 3rd quarter worth $390,000. Maven Securities LTD acquired a new position in enVVeno Medical during the 3rd quarter worth $295,000. Finally, Hohimer Wealth Management LLC acquired a new position in enVVeno Medical during the 3rd quarter worth $286,000. Institutional investors and hedge funds own 34.71% of the company's stock.

enVVeno Medical Stock Up 1.4 %

Shares of NASDAQ:NVNO traded up $0.04 during trading on Friday, reaching $2.94. 20,635 shares of the company traded hands, compared to its average volume of 107,191. enVVeno Medical has a 1-year low of $2.45 and a 1-year high of $6.48. The firm has a fifty day simple moving average of $3.23 and a 200 day simple moving average of $3.46. The firm has a market cap of $51.56 million, a P/E ratio of -2.28 and a beta of 1.38.

Remove Ads

enVVeno Medical (NASDAQ:NVNO - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.05. As a group, research analysts anticipate that enVVeno Medical will post -1.32 EPS for the current year.

enVVeno Medical Company Profile

enVVeno Medical Corporation Nasdaq: NVNO is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).